This excerpt taken from the ABII 8-K filed Nov 8, 2007.
Results of the Separation and Distribution
After the separation and distribution, we will be an independent public company owning and operating what had previously been Abraxis BioSciences proprietary products business that is currently being conducted primarily through Abraxis BioSciences Abraxis Oncology and Abraxis Research divisions. The number and identity of the holders of our common stock immediately following the distribution will be substantially the same as the number and identity of the holders of Abraxis BioScience common stock on the record date. Immediately after the distribution, we expect to have approximately 13,500 holders of shares of our common stock, and we expect that approximately 40 million shares of our common stock will be issued and outstanding based on the number of beneficial stockholders and the number of outstanding shares of Abraxis BioScience common stock as of the close of business on November 13, 2007 and the distribution ratio of one share of New Abraxis common stock for every four shares of Abraxis BioScience common stock. No fractional shares of our common stock will be issued in the distribution.
The distribution will not affect the number of outstanding shares of Abraxis BioScience common stock (which we refer to as New APP common stock following the separation and distribution) or any rights of Abraxis BioScience stockholders, although it may affect the market value of each outstanding share of Abraxis BioScience common stock.